MiMedx Group, Inc. (MDXG) SEC Filings & Earnings Calls

Merger delay or failure risk due to FTC antitrust review

“Second Request extends waiting period; merger completion subject to HSR clearance”

Acquisition adds $300M debt, increasing financial leverage and interest expense.

“new, committed debt financing in the form of a $300 million term loan”

Integration risk and potential dilution from stock consideration.

“0.4735 shares of MiMedx common stock for each share of Sanara common stock” · word for word

Medicare Reimbursement Risk

“This decline was primarily driven by the continued impact of Medicare reimbursement changes effective January 1, 2026, which adversely affected both pricing and sales volumes for these products.” · word for word

Customer Credit Deterioration Risk

“bad debt expense, which increased $5.0 million, year over year. This increase is associated with the credit deterioration of certain legacy customers.” · word for word

FDA Regulatory Risk (AXIOFILL)

“The Company received a Warning Letter from the FDA on December 21, 2023, relating to the inspections and classification of AXIOFILL.” · word for word

Acquisition Integration Risk

“the Company entered into a definitive agreement with Sanara MedTech Inc. under which the Company agreed to acquire all outstanding shares of Sanara” · word for word

Medicare reimbursement changes continue to pressure Wound business revenue and margins.

“Medicare reimbursement changes that went into effect on January 1... negatively impacting the prices of our Wound products” · word for word

Credit deterioration of legacy customers leading to higher bad debt expense.

“credit deterioration of certain, legacy customers” · word for word

Integration risk from Sanara MedTech acquisition and associated debt financing.

“acquire all of the outstanding shares of Sanara MedTech Inc. ... $300 million term loan” · word for word

Reimbursement policy disruption causing severe demand decline in wound care segment.

“new Medicare reimbursement policies ... led to significant confusion across the industry ... inconsistent implementation by the Medicare Administrative Contractors” · word for word

Guidance cut indicates sustained headwinds; profitability at risk.

“lowering full-year 2026 net sales expectations to a range of $260 to $290 million” · word for word

Medicare Reimbursement Dependency

“This decline was primarily driven by the Medicare reimbursement changes that went into effect on January 1, 2026, which resulted in reduced reimbursement rates for skin substitute products, created administrative barriers for patients to receive these products and led to lower realized pricing and volumes within the Wound Care business.” · word for word

Regulatory Classification Risk (AXIOFILL)

“The Company received a Warning Letter from the FDA on December 21, 2023, relating to the inspections and classification of AXIOFILL. The Company received a determination letter in March 2024 reaffirming the FDA’s position that AXIOFILL does not meet the regulatory classification requirements of a Human Cell, Tissue or Cellular or Tissue-based Product under S” · word for word

Medicare Reimbursement Cap Risk

“capping the reimbursement rate for skin substitutes at $127.14 per square centimeter in these care settings” · word for word

Wound Product Revenue Concentration Risk

“the business maintained a 66% to 34% split in revenue mix for the Wound and Surgical categories” · word for word

Competitive Pressure from Higher-Priced Products

“commercial challenges associated with competitive behavior in the marketplace - including the persistence of much higher priced product than any in our portfolio” · word for word

Regulatory and Legal Expense Risk

“Strategic legal and regulatory expenses $9,185 (in thousands) for 2025”

Key Person Dependency Risk

“Ricci Whitlow served as an executive officer in 2025 but she ceased serving in that position in April 2026.” · word for word

Wound Care revenue headwind from Medicare reimbursement cut may persist, pressuring top-line growth.

“Wound Care business, along with the broader market, is recovering from the January 1st Medicare reimbursement reduction at a very slow rate” · word for word

Restructuring execution risk: potential disruption to operations and employee morale.

“position of Chief Operating Officer, held by Ricci Whitlow, has been eliminated” · word for word

CMS reimbursement reform

“changing the reimbursement rate for skin substitutes from the "ASP+6%" methodology to a flat rate at $127.14 per square centimeter in these care settings” · word for word

FDA reclassification of AXIOFILL

“FDA reaffirmed its position that AXIOFILL does not meet the regulatory classification requirements under Section 361.” · word for word

Medicare reimbursement changes in Wound market may impact 2026 revenue.

“Short-term disruptions caused by Medicare reimbursement changes in the Wound market will likely have an impact on our 2026 revenue.” · word for word

Guidance implies potential slowdown in growth rate (6-12% vs 20% in FY2025).

“FY2026 net sales guidance $340-360M implies 6-12% growth vs 20% in FY2025.”

Forward-looking statements include risks related to reimbursement, regulatory approvals, and competition; no new quantitative guidance provided.

“Forward-looking statements include statements regarding: Growing expansion outside of the U.S.; Our growth expectations in 2026 and beyond, including our growth in surgery, increased funding in targeted research and expanded product portfolio; Expected results of research and development, including that our efforts will innovate and diversify our product por” · word for word

Regulatory risk from CMS 2026 reimbursement rules could impact pricing and demand.

“As we await the final 2026 reimbursement rules from the Centers for Medicare and Medicaid Services (“CMS”), we are planning for a range of potential scenarios.” · word for word

SG&A expenses increased due to higher commissions, indicating variable cost pressure from sales growth.

“The increase in SG&A was driven primarily by year-over-year increases in commissions.” · word for word

CMS reimbursement risk

“Under these proposed rules, which are scheduled for implementation on January 1, 2026, CMS is calling for a consistent payment approach for skin substitutes across the private office and Hospital Outpatient Departments settings with a fixed price of $125.38 per square centimeter.” · word for word

Regulatory litigation risk (AXIOFILL)

“The Company received a Warning Letter from the FDA on December 21, 2023, relating to the inspections and classification of AXIOFILL. On September 25, 2025, the court denied both summary judgment motions without prejudice and requested additional briefing.” · word for word